Adamis Pharmaceuticl (ADMP) 6.13 $ADMP
Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding
GlobeNewswire - Tue Mar 29, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis"
announced today that it has entered into a definitive merger agreement (the "Agreement" to acquire US Compounding, Inc. ("USC" , a privately held company registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act ("FD&C Act" , that provides prescription medications to patients, physician clinics, hospitals and surgery centers throughout most of the United States. Under the terms of the Agreement, upon the closing of the transactions contemplated by the Agreement USC will become a wholly-owned subsidiary of Adamis, all of the outstanding shares of USC will be converted into the right to receive approximately 1.62 million shares of Adamis common stock, and Adamis will assume certain secured debt obligations. The transaction is expected to close in the second quarter of 2016, subject to the satisfaction of customary closing conditions.
ADMP: 6.13 (+0.07)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 9.03 (+0.39), ADRO: 12.81 (+0.69), AVXL: 4.90 (-0.04), AMBX: (), ACH: 7.98 (-0.14), AMGN: 149.93 (+0.45), ADMP: 6.13 (+0.07), ABBV: 57.12 (+0.12)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 9.03 (+0.39), ADRO: 12.81 (+0.69), ARWR: 4.82 (+0.08), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), APTO: 3.00 (+0.29), AVXL: 4.90 (-0.04), AZN: 28.16 (-0.16), ABBV: 57.12 (+0.12), ARRY: 2.95 (+0.04)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 9.03 (+0.39), ARWR: 4.82 (+0.08), AMBX: (), CLDX: 3.78 (+0.18), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), LLY: 72.01 (+0.23), BIND: 2.20 (-0.01), BMY: 63.88 (+0.44), AZN: 28.16 (-0.16), ABBV: 57.12 (+0.12), CORT: 4.68 (+0.41)
Allergic Rhinitis Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/wnvb3w/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Allergic Rhinitis Overview - Therapeutics Development - Pipeline Products for Allergic Rhinitis - Overview - Pipeline Products for Allergic Rhinitis - Comparative Analysis - Allergic Rhinitis - Therapeutics under Development by Companies - Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes - Allergic Rhinitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Allergic Rhinitis - Products under Development by Companies - Allergic Rhinitis - Products under Investigation by Universities/Institutes - Allergic Rhinitis - Companies Involved in Therapeutics Development - 3M Drug Delivery Systems - 3SBio Inc. - Accolade Pharma LLC - Adamis Pharmaceuticals Corporation - AFFiRiS AG - ALK-Abello A/S - Ampio Pharmaceuticals, Inc. - AnaptysBio, Inc. - Axikin Pharmaceuticals, Inc. - BioTech Tools s.a. - Chong Kun Dang Pharmaceutical Corp. - ELORAC, Inc. - FAES Farma SA - Fountain Biopharma Inc. - GenMont Biotech Inc. - GlaxoSmithKline Plc - HAL Allergy BV - Hanmi Pharmaceuticals, Co. Ltd. - Hisamitsu Pharmaceutical Co., Inc. - Johnson & Johnson - Laboratorios LETI S.L. - Ligand Pharmaceuticals, Inc. - Marinomed Biotechnologie GmbH - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm Co., Ltd. - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Panmira Pharmaceuticals, LLC. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/wn...c_rhinitis
PFE: 29.64 (-0.43), ADMP: 6.13 (+0.07), AMPE: 2.25 (-0.01), GSK: 40.55 (-0.15), NKTR: 13.75 (+0.18), JNJ: 108.20 (-0.78), MRK: 52.91 (-0.31), NVS: 72.44 (-0.11)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 9.03 (+0.39), ADRO: 12.81 (+0.69), AMBX: (), ARQL: 1.60 (+0.02), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), APTO: 3.00 (+0.29), ATNM: 1.99 (-0.06), AVXL: 4.90 (-0.04), ABBV: 57.12 (+0.12)
Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 8.82 (+0.14), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), ACOR: 26.45 (+0.07), CLBS: 0.75 (-0.04), AZN: 28.16 (-0.16), ARRY: 2.95 (+0.04)
Adamis Pharmaceuticals enters into Series A-1 convertible preferred stock and warrants private placement
M2 - Wed Jan 27, 4:52AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) stated on Tuesday that it has received gross cash proceeds of approximately USD5m from
Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding
GlobeNewswire - Tue Mar 29, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis"
announced today that it has entered into a definitive merger agreement (the "Agreement" to acquire US Compounding, Inc. ("USC" , a privately held company registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act ("FD&C Act" , that provides prescription medications to patients, physician clinics, hospitals and surgery centers throughout most of the United States. Under the terms of the Agreement, upon the closing of the transactions contemplated by the Agreement USC will become a wholly-owned subsidiary of Adamis, all of the outstanding shares of USC will be converted into the right to receive approximately 1.62 million shares of Adamis common stock, and Adamis will assume certain secured debt obligations. The transaction is expected to close in the second quarter of 2016, subject to the satisfaction of customary closing conditions. ADMP: 6.13 (+0.07)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 9.03 (+0.39), ADRO: 12.81 (+0.69), AVXL: 4.90 (-0.04), AMBX: (), ACH: 7.98 (-0.14), AMGN: 149.93 (+0.45), ADMP: 6.13 (+0.07), ABBV: 57.12 (+0.12)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 9.03 (+0.39), ADRO: 12.81 (+0.69), ARWR: 4.82 (+0.08), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), APTO: 3.00 (+0.29), AVXL: 4.90 (-0.04), AZN: 28.16 (-0.16), ABBV: 57.12 (+0.12), ARRY: 2.95 (+0.04)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 9.03 (+0.39), ARWR: 4.82 (+0.08), AMBX: (), CLDX: 3.78 (+0.18), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), LLY: 72.01 (+0.23), BIND: 2.20 (-0.01), BMY: 63.88 (+0.44), AZN: 28.16 (-0.16), ABBV: 57.12 (+0.12), CORT: 4.68 (+0.41)
Allergic Rhinitis Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/wnvb3w/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Allergic Rhinitis Overview - Therapeutics Development - Pipeline Products for Allergic Rhinitis - Overview - Pipeline Products for Allergic Rhinitis - Comparative Analysis - Allergic Rhinitis - Therapeutics under Development by Companies - Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes - Allergic Rhinitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Allergic Rhinitis - Products under Development by Companies - Allergic Rhinitis - Products under Investigation by Universities/Institutes - Allergic Rhinitis - Companies Involved in Therapeutics Development - 3M Drug Delivery Systems - 3SBio Inc. - Accolade Pharma LLC - Adamis Pharmaceuticals Corporation - AFFiRiS AG - ALK-Abello A/S - Ampio Pharmaceuticals, Inc. - AnaptysBio, Inc. - Axikin Pharmaceuticals, Inc. - BioTech Tools s.a. - Chong Kun Dang Pharmaceutical Corp. - ELORAC, Inc. - FAES Farma SA - Fountain Biopharma Inc. - GenMont Biotech Inc. - GlaxoSmithKline Plc - HAL Allergy BV - Hanmi Pharmaceuticals, Co. Ltd. - Hisamitsu Pharmaceutical Co., Inc. - Johnson & Johnson - Laboratorios LETI S.L. - Ligand Pharmaceuticals, Inc. - Marinomed Biotechnologie GmbH - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm Co., Ltd. - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Panmira Pharmaceuticals, LLC. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/wn...c_rhinitis
PFE: 29.64 (-0.43), ADMP: 6.13 (+0.07), AMPE: 2.25 (-0.01), GSK: 40.55 (-0.15), NKTR: 13.75 (+0.18), JNJ: 108.20 (-0.78), MRK: 52.91 (-0.31), NVS: 72.44 (-0.11)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 9.03 (+0.39), ADRO: 12.81 (+0.69), AMBX: (), ARQL: 1.60 (+0.02), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), APTO: 3.00 (+0.29), ATNM: 1.99 (-0.06), AVXL: 4.90 (-0.04), ABBV: 57.12 (+0.12)
Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 8.82 (+0.14), ADMP: 6.13 (+0.07), AMGN: 149.93 (+0.45), ACOR: 26.45 (+0.07), CLBS: 0.75 (-0.04), AZN: 28.16 (-0.16), ARRY: 2.95 (+0.04)
Adamis Pharmaceuticals enters into Series A-1 convertible preferred stock and warrants private placement
M2 - Wed Jan 27, 4:52AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) stated on Tuesday that it has received gross cash proceeds of approximately USD5m from
